Antiviral therapy of hepatitis C - present and future

Journal of Hepatology

Volumn 17, Issue SUPPL. 3, 1993, Pages

  Hoofnagle, Jay H ^a   Di Bisceglie, Adrian M ^a   Shindo, Michiko ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Antiviral therapy; Chronic hepatitis; Cirrhosis; Controlled trials; Hepatitis C virus; Interferon; Polymerase chain reaction; Ribavirin

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE; ACICLOVIR; ALPHA INTERFERON; BETA INTERFERON; COLONY STIMULATING FACTOR; FOSCARNET; GAMMA INTERFERON; GANCICLOVIR; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LEVAMISOLE; PREDNISONE; RIBAVIRIN; SURAMIN; THYMOSIN; TUMOR NECROSIS FACTOR; VIDARABINE; ZIDOVUDINE;

CHRONIC HEPATITIS; CONFERENCE PAPER; HEPATITIS NON A NON B; HEPATITIS VIRUS NON A NON B; HUMAN; LIVER CIRRHOSIS; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FORECASTING; HEPATITIS C; HUMAN; INTERFERON-ALPHA; PREDICTIVE VALUE OF TESTS; RECURRENCE;

EID: 0027478886     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(05)80438-6     Document Type: Article

References (31)

1. Treatment of chronic non-A non-B hepatitis with recombinant human alpha interferon a preliminary report
2. Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A, non-B hepatitis
3. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial
4. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial
5. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France
6. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis
7. One-year treatment of chronic non-A, non-B hepatitis with interferon alfa-2b
8. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience
9. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group
10. Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis: preliminary results of a randomized, controlled trial
11. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C
12. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection
13. Detection of hepatitis C viral sequences in non-A, non-B hepatitis
14. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis
15. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay
16. Hepatitis C virus antibodies in chronic active hepatitis: pathogenic factor or false-positive result?
17. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance
18. Autoimmune chronic hepatitis exacerbated by alpha-interferon
19. Acute exacerbation of liver disease during alpha interferon therapy for chronic hepatitis C
20. Recurrence of hepatitis C infection following orthotopic liver transplantation
21. Transmission of hepatitis C virus by organ transplantation
22. Resolution of acute hepatitis C after therapy with natural beta interferon
23. Pilot study of interferon alpha-2a therapy in preventing chronic evoluation of acute hepatitis C
24. A randomized controlled trial of alpha-interferon in acute posttransfusion C hepatitis (Abstract)
25. Predictors of relapse and response to re-treatment in patients with an initial response to recombinant alpha interferon (rIFN) therapy for chronic hepatitis C (Abstract)
26. A randomized controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
27. Serum IgM antibody to HCV: a reliable marker of active hepatitis C (Abstract)
28. Hepatitis C virus antigen in hepatocytes: immunomorphologic detection and identification
29. Biochemistry and clinical applications of ribavirin
30. Ribavirin treatment for chronic hepatitis C
31. Ribavirin therapy for 6 months in patients with chronic hepatitis C (Abstract)